A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Brief description of study

The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment for advanced or metastatic solid tumors with a proven ALK, ROS or NTRK 1-3 gene rearrangement. An investigational medication or drug is one that has not been approved by the U.S. Food & Drug Administration (FDA).

Clinical Study Identifier: s19-00440
ClinicalTrials.gov Identifier: NCT03093116

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.